Bruton’s tyrosine kinase (BTK) has been implicated in the pathogenesis of B-cell lymphomas through its role in the B-cell receptor (BCR) signaling cascade, providing a strong rationale for its inhibition as a therapeutic strategy [32]. Here, BTK is linked to B-cell non-Hodgkin lymphoma.